Presence of tobramycin in blood and urine during selective decontamination of the digestive tract in critically ill patients, a prospective cohort study by Oudemans-van Straaten, Heleen M et al.
RESEARCH Open Access
Presence of tobramycin in blood and urine during
selective decontamination of the digestive tract in
critically ill patients, a prospective cohort study
Heleen M Oudemans-van Straaten
1*, Henrik Endeman
1, Robert J Bosman
1, Milly E Attema-de Jonge
2,
Marc L van Ogtrop
3, Durk F Zandstra
1 and Eric JF Franssen
2
Abstract
Introduction: Tobramycin is one of the components used for selective decontamination of the digestive tract
(SDD), applied to prevent colonization and subsequent infections in critically ill patients. Tobramycin is
administered in the oropharynx and gastrointestinal tract and is normally not absorbed. However, critical illness
may convey gut barrier failure. The aim of the study was to assess the prevalence and amount of tobramycin
leakage from the gut into the blood, to quantify tobramycin excretion in urine, and to determine the association
of tobramycin leakage with markers of circulation, kidney function and other organ failure.
Methods: This was a prospective observational cohort study. The setting was the 20-bed closed format-mixed ICU
of a teaching hospital. The study population was critically ill patients with an expected stay of more than two days,
receiving SDD with tobramycin, polymyxin-E and amphotericin-B four times daily in the oropharynx and stomach.
Tobramycin concentration was measured in serum (sensitive high performance liquid chromatography - mass
spectrometry/mass spectrometry (HLPC-MS/MS) assay) and 24-hour urine (conventional immunoassay), in 34
patients, 24 hours after ICU admission, and in 71 patients, once daily for 7 days. Tobramycin leakage was defined
as tobramycin detected in serum at least once (> 0.05 mg/L). Ototoxicity was not monitored.
Results: Of the 100 patients with available blood samples, 83 had tobramycin leakage. Median highest serum
concentration for each patient was 0.12 mg/L; 99% of the patients had at least one positive urinary sample (> 0.5
mg/L), 49% had a urinary concentration ≥ 1 mg/L. The highest tobramycin serum concentration was significantly
associated with vasopressor support, renal and hepatic dysfunction, and C-reactive protein. At binary logistic
regression analysis, high dopamine dose and low urinary output on Day 1 were the significant predictors of
tobramycin leakage. Nephrotoxicity could not be shown.
Conclusions: The majority of acute critically ill patients treated with enteral tobramycin as a component of SDD
had traces of tobramycin in the blood, especially those with severe shock, inflammation and subsequent acute
kidney injury, suggesting loss of gut barrier and decreased renal removal. Unexpectedly, urinary tobramycin was
above the therapeutic trough level in half of the patients. Nephrotoxicity could not be demonstrated.
Introduction
Selective decontamination of the digestive tract (SDD)
reduces the number of Gram-negative and yeast infec-
tions in intensive care patients and reduces hospital
mortality [1,2]. It does so by eradicating Gram-negative
bacteria and yeasts from the intestinal tract, while pre-
serving Gram-positive and anaerobic bacteria. Treat-
ment consists of the local application of tobramycin,
polymyxin and amphotericin in the oropharynx and gas-
trointestinal tract. If the gut barrier is intact, the antibio-
tics exert their effect in the digestive tract and are not
absorbed. However, conditions such as sepsis, shock or
major surgery can convey gut barrier failure [3] and
may result in the leakage of the antibiotics from the gut
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readily leak, since its molecular weight is the smallest of
the active constituents of SDD (1,425 D). Furthermore,
critical illness may additionally be associated with acute
kidney injury (AKI), hampering removal of the leaked
tobramycin [4]. If tobramycin leakage from the gut per-
sists over time and attains significant concentrations in
the blood, accumulation might cause harm to the kidney
and the inner ear [5,6]. We hypothesized that during
critical illness some of the enteral administered tobra-
mycin leaks to the systemic circulation and is subse-
quently excreted in urine.
The aim of this prospective observational cohort study
in critically ill patients receiving SDD was to determine
whether and to what extent the enterally administered
tobramycin leaks to the circulation and is excreted in
urine, and whether we can predict the leakage of tobra-
mycin with markers of circulation, kidney function and
other organ failure.
Materials and methods
Study design and setting
This prospective observational cohort study was con-
ducted in a 20-bed closed format general ICU of a
teaching hospital. SDD is routinely prescribed to all cri-
tically ill patients with an expected ICU stay of more
than two days. We first measured the presence of tobra-
mycin in blood and urine in a cohort of 20 patients dur-
ing the first day of ICU admission. Because of the great
proportion of patients with tobramycin leakage and
because we wanted to assess whether tobramycin leak-
age continued after Day 1, we continued measuring
tobramycin in blood and urine in a second cohort. In
this cohort, tobramycin was measured daily during the
first week of ICU admission. The institutional review
board approved the study according to European and
Dutch legislation. Written informed consent was
obtained from the patient or his legal representative a
priori or delayed but within the first 24 hours.
Patients
Subsequent adult critically ill patients acutely admitted
to the ICU were eligible for inclusion if the expected
duration of treatment with SDD was more than two
days. Exclusion criteria were treatment with tobramycin
or gentamicin intravenously in the 72-h preceding ICU
admission and during the study period. Patients with a
positive baseline tobramycin concentration were a priori
excluded from analysis.
Selective decontamination of the digestive tract
The SDD regimen consisted of an enteral and an oral
part. At six-hour intervals a solution containing poly-
myxin-E 100 mg, tobramycin 80 mg and amphotericin-B
500 mg was administered via the gastric tube. At the
same time, an oral paste, containing 2% polymyxin E,
2% tobramycin and 2% amphotericin B, was applied in
the mouth.
Study protocol
After inclusion in the study, a baseline blood sample
was taken directly after ICU admission for measurement
of tobramycin concentration (Day 1). Baseline markers
of organ function were determined, and oral and rectal
surveillance cultures were taken according to routine
clinical practice. Thereafter, the first dose of SDD was
administered via the gastric tube, and repeated at six-
hour intervals until discharge from the unit. Subsequent
blood samples and a portion of the 24-h urine were
taken for determination of tobramycin 24-h after admis-
sion in the first cohort, and once daily for seven days in
the second cohort.
Measurement of tobramycin in serum and urine
Tobramycin in serum was quantified with a previously
described and validated extremely sensitive HLPC-MS/
MS assay [7]. This simple, rapid and sensitive method
detects tobramycin with a lower limit of quantification
of 0.05 mg/l. The accuracy was good; within-day and
between-day precisions were less than 12%. For the
determination of tobramycin in urine we used a conven-
tional immunoassay method (lower limit of quantitation
0.5 mg/l) (Emit
® 2000, Siemens Healthcare Diagnostics
Inc., Newark, DE 19714, USA). Notably, the method
used in serum was 10-fold more sensitive than the con-
ventional assay used for urine.
Clinical measurements
Apart from routine clinical measurements of circulation,
gas exchange, fluid balance, renal and hepatic function,
severity of illness was scored using the Acute Physiology
and Chronic Health Evaluation (APACHE II, III and IV)
systems [8,9] over the first 24-hours of ICU admission.
The Sequential Organ Failure Assessment (SOFA) score
[10] as defined by the Dutch National Intensive Care
Evaluation [11] was measured daily. Renal function was
classified according to the RIFLE (Risk, Injury, Failure)
System [12]. Risk was scored as 1, Injury as 2 and Fail-
ure as 3.
Endpoints and definitions
The primary endpoint of the study was the proportion
of patients with tobramycin leakage into the blood cir-
culation. Tobramycin leakage was defined as at least
once a detectable serum tobramycin sample (> 0.050
mg/L), and no tobramycin leakage as no tobramycin
detectible in serum during the entire study period. Sec-
ondary endpoints were the concentration of tobramycin
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cin leakage and markers of circulation, renal and other
organ function. A detectable urine concentration was
defined as ≥ 0.50 mg/L. Due to the less sensitive method
used in urine, the detectable concentration in urine was
higher than in serum. A therapeutic trough concentra-
tion was defined as ≥ 1 mg/L [13].
Data analysis
We analyzed the two cohorts both separately and
together. When analyzing them together, the results
from the second cohort became statistically stronger
due to the greater sample size. Therefore, we present
the data of the two cohorts together. Values are pre-
sented as mean (standard deviation, SD) and/or median
(interquartile range, IQR). To compare tobramycin con-
centrations at different time points, we used the Wil-
coxon Signed Ranks test. Due to differences in ICU stay,
follow-up time varied between patients. We, therefore,
analyzed two single markers of tobramycin leakage per
patient. The quantitative marker, the highest serum
tobramycin concentration, was used for correlation with
clinical markers of circulation and organ failure at the
same day and with markers on ICU admission day. The
qualitative marker, tobramycin leakage (see definitions),
was used to compare patients with tobramycin leakage
to those without tobramycin leakage. For correlations
we used the two-sided Spearman Rank test and for
comparisons between groups the unpaired T-test or
Mann-Whitney U test for continuous values and the
two-sided Fisher’s exact test for non-parametric
variables.
To determine the variables independently predicting
tobramycin leakage, binary logistic regression analysis
was used. All of the covariates that were different at
unadjusted analysis with a P-value < 0.10 were entered
simultaneously into the model. Backward stepwise
regression analysis was applied by removing the least
significant value step by step until only significant deter-
minants remained. Odds ratios (OR) and their 95% con-
fidence intervals (95% CI) are reported. We used SPSS
®
version 18.0 (IBM corporation, New York, USA).
Results
A total of 105 patients was included in this study. Base-
l i n ec h a r a c t e r i s t i c sa r ep r e s e n t e di nT a b l e1 .N o n eo f
the patients received additional tobramycin suppositories
or tobramycin nebulization, and in none of the patients,
tobramycin dose differed from the protocol. In 34 con-
secutive patients (that is, 20 in the first cohort and 14 in
the second), tobramycin was measured during the day
of ICU admission only, and in 71 consecutive patients,
tobramycin was measured daily from Day 1 to Day 7, or
until discharge from the ICU. A blood sample was
missing in five patients, leaving 100 patients with blood
samples at Day 1, and two patients had no urinary sam-
ple. A total of 265 blood samples and 277 urinary sam-
ples were analyzed.
Table 1 Baseline characteristics of the 105 patients
Mean ± SD Nr (%) or
Median (IQR)
Age (ys)* 65.24 ± 14.57 66 (55.5 to 75.0)
Male sex 70 (66.7)
Body weight (kgs)* 81.1 ± 17.3 80 (70 to 90)
BMI 27.2 ± 5.6 26.3 (23.5 to 29.3)
Admission type
￿ Medical 79 (75.2)
￿ Cardiosurgical 10 (9.5)
￿ Other surgical 16 (15.2)
Sepsis 34 (32.4)
CRP admission (mg/L) 89.1 ± 116 26.0 (3.0 to 160.6)
APACHE II score 27.4 ± 9.0 26.5 (20.0 to 34.0)
APACHE II PM 0.57 ± 0.28 0.59 (0.31 to 0.84)
APACHE III score 102 ± 35 97.5 (73.0 to 125.8)
APACHE IV PM 0.55 ± 0.31 0.56 (0.26 to 0.85)
SOFA admission 9 ± 4 9 (7 to 11)
Mechanical ventilation 104 (99.0)
MAP admission (mmHg) 80.6 ± 21.9 79 (62.0 to 94.0)
Dopamine admission (μg/kg/
minute)
11.1 ± 13.7 5.9 (2.4 to 14.3)
Noradrenalin admission (μg/kg/
minute)
0.05 ± 0.13 0.00 (0.00 to 0.04)
Lowest pH
a 7.2 ± 0.18 7.2 (7.08 to 7.30)
Lowest bicarbonate
a 17.8 ± 6.2 17.3 (13.8 to 22.3)
Lowest PO2 (mmHg)
a 74.0 ± 23.0 70 (60.3 to 82.0)
PF ratio (mmHg/fraction) 244 ± 144 206 (151 to 294)
Creatinine before admission
b 80 ± 31 77 (56 to 98)
Creatinine (μmol/L) 118 ± 86.6 98.5 (71.0 to 133.3)
Urea (mmol/L) 11 ± 7 8 (6 to 14)
Urinary output d1(ml) 2,711 ± 1,851 2,378 (1,174 to
3,969)







Chronic dialysis 2 (2%)
Bilirubin (μmol/L) 14 ± 17 9 (5 to 16)
Hemoglobin (mmol/L) 6.8 ± 1.6 6.8 (5.8 to 8.2)
Platelets (giga) 236 ± 144 209 (151 to 298)
* Normally distributed variables.
APACHE, Acute Physiology and Chronic Health Evaluation; IQR, interquartile
range; PM, predicted mortality; SAPS, Simplified Acute Physiology Score; SD,
standard deviation; SOFA, Sequential organ failure score.
a within two hours of ICU admission,
b creatinine of the chronic dialysis
patients not included,
c RIFLE acronym for risk of acute kidney injury: Risk = 1,
Injury = 2, Failure = 3. The chronic dialysis patients were excluded from the
RIFLE classification.
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samples (83%) had once had at least a detectable serum
tobramycin concentration (> 0.050 mg/L). Tobramycin
concentrations in serum during the first seven days are
represented in Figure 1. Serum tobramycin concentra-
tion at Days 3, 4 and 5 was significantly higher than at
Day 2 (P < 0.05), but stabilized thereafter. The number
of patients decreased per day due to discharge or death.
The median highest serum tobramycin concentration
per patient was 0.120 (IQR 0.063 to 0.232) mg/L. A
serum concentration > 1 mg/L was detected once in
one patient at 48-h after ICU admission (Figure 1).
A total of 102 patients (99%) had at least one urinary
sample with detectable tobramycin (> 0.50 mg/L), while
50 patients (49%) had at least one urinary sample with a
tobramycin concentration ≥ 1 mg/L. The tobramycin
concentration in urine increased by day of admission up
to Day 5 and remained fairly constant thereafter (Figure
2). The proportion of patients with a urinary tobramycin
concentration > 1 mg/L increased by admission day, and
was more than half from Day 4. The median total
amount of tobramycin recovered in urine per day varied
between 2 to 4.2 mg/day (about 1% of the daily dose)
and was 25 mg/day at most (8% of the daily dose).
We correlated highest serum tobramycin concentra-
tion with markers of organ failure and inflammation
on the same day and on those on the day of ICU




Day of ICU admission 
a  1  2  3  4  5  6  7 
Nr patients  100  59  37  23  19  16  11 
Median 
mg/L 
0.060  0.082  0.120  0.098  0.089  0.097  0.120 
Maximum 
mg/L 
0.510  1.300  0.680  0.560  0.470  0.360  0.270 
Detectable 
b 
Nr patients (%) 
60 (60)  46 (78)  30 (81)  18 (78)  17 (89)  12 (75)  9 (81) 
a Samples were taken at the end of the day. 
b Detectable: serum tobramycin concentration > 0.050 mg/L 
Figure 1 Serum tobramycin concentrations and percentage of patients with detectable serum tobramycin (> 0.050 mg/L).D a y0 :o n
admission. Day 1 to Day 7: serum tobramycin concentration at the end of the day.
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received additional noradrenalin. Only the strongest
correlations are reported. Highest tobramycin concen-
tration correlated positively with C-reactive protein
(CRP) (r = 0.26, P = 0.01), urea (r = 0.21, P =0 . 0 4 7 )
and bilirubin (0.30, P = 0.005) on admission, to highest
dopamine dose (r = 0.21, P = 0.04), noradrenalin dose
(r = 0.20, P = 0.05) and urinary output (ml/kg/h) on
Day 1 (r = -0.25, P = 0.01), and to RIFLE based on
creatinine during the study period (r = 0.22, P = 0.03),
and correlated negatively with gastric retention on Day
1 (r = -0.24, P = 0.023). Highest tobramycin concentra-
tion was significantly higher in patients without AKI
compared to those with any degree of AKI according
to RIFLE, (median 97 (IQR 51 to 172) versus 130 (IQR
84 to 285), P = 0.04). Highest serum tobramycin
concentration was not significantly related to total
SOFA and APACHE scores.
We subsequently compared the clinical characteristics
of the patients with tobramycin leakage to those with-
out. It appeared that differences in markers of organ
failure were most pronounced at the day of ICU admis-
sion. These are presented in Table 2. Patients with
tobramycin leakage received more dopamine and had a
lower diuresis at the day of ICU admission; they tended
to be older, to receive more noradrenalin, to have a
higher bilirubin and tended to have a higher CRP. In
subsequent binary logistic regression analysis, dopamine
dose (odds ratio 1.13 (95% CI 1.01 to 1.34) and urinary
output on Day 1 (odds ratio 0.54 (95% CI 0.33 to 0.90)
remained as significant predictors of tobramycin leakage.




Day of ICU admission 
a  1  2  3  4  5  6  7 
Nr patients  99  57  40  31  22  16  12 
Median 
mg/L 
0.00  0.356  1.035  1.000  1.250  1.350  1.450 
Maximum 
mg/L 
24.7  10  7.1  9.0  10.0  17.0  18.0 
>1mg/L
b 
Nr patients (%) 
22 (22)  22 (39)  20 (50)  16 (52)  15 (61)  10 (63)  7 (78) 
a Samples were taken at the end of the day. 
b the therapeutic through level of tobramycin 
Figure 2 Tobramycin concentrations in 24-h urine and percentage of patients with a urinary tobramycin concentration > 1.0 mg/L).
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gastric retention did not confound the model.
To estimate possible renal toxicity of the leaked tobra-
mycin, we compared the serum creatinine at discharge
with creatinine pre hospital admission, and the change in
creatinine, expressed as the creatinine at discharge divided
by creatinine pre ICU admission,e x c l u d i n gt h et h r e e
chronic hemodialysis patients. Creatinine pre-admission
could be retrieved from 100/105 patients. We found
that the two were not significantly different between










Age (years) 62 (49.5 to 69.5) 68 (59.0 to 76.0) 0.06
BMI 25.2 (22.7 to 27.7) 27.2 (24.1 to 29.3) 0.11
SOFA score 10 (7 to 11) 9 (7 to 12) 0.60
APACHE II score 25 (21 to 33) 27 (20 to 35) 0.61
APACHE II PM 59 (40 to 83) 61 (31 to 84) 0.78
SAPS II score 58 (46 to 66) 59 (44 to 73) 0.81
SAPS II PM 64 (37 to 78) 65 ((33 to 87) 0.79
APACHE III score 101 (70 to 124) 97 (73 to 132) 0.96
APACHE IV PM 61 (25 to 82) 56 (25 to 90) 0.87
Sepsis 5 (29.4) 27 (32.5) 1.00
CRP (mg/L) 3 (2 to 94) 37 (4 to 169) 0.06
Lowest MAP (mmHg) 78 (65 to 99) 79 (61 to 94) 0.90
Dopamine dose (μg/kg/minute) 3.3 (2.2 to 5.9) 6.7 (2.8 to 17.2) 0.02
Noradrenalin dose (μg/kg/minute) 0.00 (0.00 to 0.00) 0.00 (0.00 to 0.05) 0.09
Fluid balance (ml) 3,450 (548 to 4,646) 3,074 (1,323 to 4,528) 0.99
Lowest PO2 mmHg 75 (61.0 to 83.5) 70 (60.8 to 82.0) 0.53
PF ratio (mmHg/fraction) 206 (125 to 276) 206 (156 to 300) 0.72
Lowest pH 7.21 (7.08 to 7.27) 7.21 (7.09 to 7.29) 0.68
Creatinine before hospital admission (μmol/L) 83 (64.0 to 101.5) 77 (56.0 to 96.5) 0.43
Creatinine admission (μmol/L) 98 (75 to 129) 99 (69 to 144) 0.92
Creatinine d2 (μmol/L) 87 (59 to 101) 95 (70 to 144) 0.24
Urinary output (ml) 3,645 (1,893 to 4,608) 2,150 (1,092 to 3,585) 0.05
Urinary output (ml/kg/h) 1.8 (1.07 to 2.85) 1.0 (0.55 to 1.88) 0.04
RIFLE 1,2,3
c
0 13 (77) 45 (56) 0.40
1 2 (12) 11 (14)
2 1 (6) 14 (17)
3 1 (6) 11 (14)
Bilirubin (μmol/L) 6 (4 to 13) 9 (6 to 17) 0.07
Hemoglobin (mmol/L) 7.5 (5.5 to 8.8) 6.8 (5.9 to 8.2) 0.34
Platelets (giga) 214 (165 to 276) 200 (148 to 300) 0.75
Gastric retention (ml/day) 450 (215.0 to 777.0) 250 (112.5 to 660.0) 0.18
Outcome
CVVH during ICU admission 3 (18%) 22 (27%) 0.55
Duration mechanical ventilation (h) 42 (32 to 76) 62 (25 to 114) 0.72
LOS ICU (days) 2.2 (1.8 to 4.0) 3.4 (2.0 to 6.2) 0.29
Creatinine hospital discharge (μmol/L) 99 (59 to 129) 82 (58 to 147) 0.69
Creatinine hospital discharge/creatinine pre-admission 1.13 (1.02 to 1.32) 1.16 (1.00 to 1.54) 0.81
Mortality hospital n (%) 6 (35) 25 (30) 0.46
Values in median (interquartile range). APACHE, Acute Physiology and Chronic Health Evaluation; CVVH, continuous venovenous hemofiltration; PF, ratio PaO2
(mmHg)/inspiratory oxygen (fraction); PM, predicted mortality; SAPS, Simplified Acute Physiology Score; SOFA, Sequential organ failure score.
a within two hours
of ICU admission,
b creatinine of the chronic dialysis patients not included,
c RIFLE acronym for risk of acute kidney injury: Risk = 1, Injury = 2, Failure = 3
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nificantly correlate with highest serum tobramycin con-
centration (P = 0.29). None of the patients with AKI
remained dialysis-dependent after hospital discharge.
Discussion
The present prospective cohort study in critically ill
patients acutely admitted to the ICU receiving enteral
tobramycin as a component of SDD showed that traces
of tobramycin could be detected in the serum of 83% of
the patients, indicating gut barrier failure. Tobramycin
leakage was associated with the severity of shock and
inflammation at ICU admission and subsequent AKI;
however, nephrotoxicity could not be detected. The
study further shows that tobramycin was detectable in
urine in 99% of the patients, and that the urinary con-
centration was above the therapeutic trough level (> 1
mg/L) in half of the patients.
Clinical determinants of tobramycin leakage
SDD is used in critically ill patients because it effectively
reduces colonization of the oropharyngeal and intestinal
mucosa and subsequent infections with Gram-negatives
and yeasts [1,2]. It is general l ya s s u m e dt h a tt h ee n t e r -
ally administered antibiotics remain in the digestive
tract and are not absorbed. This was the case in 17% of
the critically ill patients in this study. In contrast, the
present study shows that in the majority of acute criti-
cally ill patients receiving SDD, trace amounts of the
enteral tobramycin leak into the bloodstream. Tobramy-
cin leakage was best explained by the degree of shock at
ICU admission, as roughly reflected by dopamine dose
and urinary output at the day of admission, but less so
at subsequent days. Highest tobramycin concentration
was associated with markers of circulatory dysfunction,
liver dysfunction and inflammation on the day of ICU
admission, and to acute renal impairment during the
study period as reflected by the RIFLE class. Tobramy-
cin leakage was not associated with total SOFA score,
which also includes neurological dysfunction. Unfortu-
nately, we did not routinely measure lactate at the time
of the study and could, therefore, not correlate this mar-
ker of poor circulation with highest tobramycin. These
results suggest that gut barrier failure was likely due to
temporary gut ischemia due to shock and systemic
inflammation, and that the absorbed tobramycin slightly
accumulated until Day 5 due to AKI. Although it may
be hypothesized that small amounts of tobramycin
always leak into the circulation and that blood concen-
trations only rise in patients with some kidney injury,
this is likely not the case, because in 17% of the patients
tobramycin was never detected in the blood despite
using an extremely sensitive detection method. Possible
sequels of tobramycin leakage will be discussed.
Risk of toxicity
Tobramycin toxicity is associated with high prolonged
serum concentrations [14,15] and especially high trough
concentrations [16]. Persistent leakage of tobramycin
may be toxic, especially for the inner ear and kidneys
[5,6,17]. Tobramycin could be detected in the serum in
83% of the patients when using a sensitive method
(detection > 0.050 mg/L). Previous studies using a
slightly less sensitive method (detection > 0.18 mg/L)
found detectible serum tobramycin concentrations in 9/
15 ventilated patients (> 1 mg/L in 2 patients) [18], in
56% of the samples from 22 intensive care patients
receiving SDD for 10 days with concentrations > 2 mg
in the 2 patients with renal failure [19], and in 12/19
critically ill patients treated with continuous venovenous
hemofiltration (> 1 mg in 4 patients) [20]. We found a
concentration > 1 mg/L only once and a steady state
after repeated administrations (see Figure 1). Recently, a
serum tobramycin concentration of 18.9 mg/L was
reported 30 days after oesophago-gastrectomy. The
patient developed AKI and remained dialysis dependent.
Toxic tobramycin concentrations were likely explained
by colonic ischemia, motility disorders, a blind jejunal
loop and additional suppositories [21]. Mild toxic effects
are difficult to determine in critically ill patients without
a randomized controlled design due to the complexity
of critical illness and its associated multiple drug use
and also because tobramycin leakage during the first
ICU day was already associated with oliguria at ICU
admission, before any tobramycin was administered. We
could not show major kidney injury due to tobramycin
leakage, because creatinine at hospital discharge and
change in creatinine (at discharge divided by pre-hospi-
tal admission) were not higher in the patients with
tobramycin leakage. We did not take audiograms in our
patients, thus otoxicity was not monitored. Fortunately,
tobramycin leakage in our patients was not associated
with crude outcome markers like ICU stay or hospital
mortality. To prevent possible toxicity of SDD, monitor-
ing blood tobramycin concentrations should be consid-
ered in patients with a prolonged vasopressor-dependent
circulation, renal dysfunction, enteral dysmotility and
especially when adding tobramycin suppositories or neb-
ulization in patients. When serum concentrations
remain > 1 mg/L, enteral tobramycin dose should be
reduced.
Antimicrobial effects
Although trace concentrations of tobramycin could be
detected in the blood in the majority of the patients,
blood concentrations were above the therapeutic trough
concentration only once and far from sufficient to treat
blood stream infections. In contrast, urinary tobramycin
concentrations unexpectedly were above the therapeutic
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and in two-thirds at the end of the first week of ICU
admission. Urinary concentrations up to 24 mg/L were
measured and concentrations increased until Day 5.
T o b r a m y c i ni se n t i r e l yr e m o v e df r o mt h eb o d yb yg l o -
merular filtration, 85% within 24 hours when renal func-
tion is normal [4,15,22]. The remaining drug
accumulates, particularly in r e n a lc o r t i c a lt i s s u e ,a n di s
slowly excreted by urine for 10 to 20 days [23,24],
explaining the increasing proportion of patients with
urinary concentrations > 1 mg/L in time. Urinary tobra-
mycin concentration depends on plasma concentration,
on glomerular filtration rate with a delay, and on tubu-
lar concentration ability. Urinary concentrations are
thus manifold higher than plasma concentrations, even
with renal dysfunction as present in some of our
patients. The presence of tobramycin in urine in
patients with gut barrier failure, as first shown in this
study, may contribute to the prevention of urinary tract
colonization with tobramycin sensitive strains. Unfortu-
nately, we cannot support this assumption with data
from urinary cultures. In the past, we have discontinued
taking urinary cultures as part of the SDD surveillance,
because we almost never found Gram negative bacteria
in urinary cultures. Elimination of the enteral focus of
urinary Gram negatives is one mechanism explaining
the absence of urinary Gram negatives; however, direct
urinary antimicrobial effects by urinary tobramycin ori-
ginating from the gut, as demonstrated in the present
study, may additionally prevent urinary tract coloniza-
tion with Gram-negative bacteria in the setting of the
low prevalence of multi-resistant strains.
Risk of resistance
Prolonged exposure of blood and urine to low concen-
trations of tobramycin might promote tobramycin resis-
tance. However, the fear of tobramycin resistance in the
setting of SDD does not seem realistic. Resistance is
more likely to occur if a high bacterial load is exposed
to sub-therapeutic antibiotic concentrations. The highest
bacterial load in the ICU resides in the patient’sg u t .
During SDD gut concentrations are extremely high (320
mg/day), creating unfavorable conditions for the devel-
opment of resistance. This is supported by a Cochrane
meta-analysis concluding that the risk of resistance
using SDD was appropriately explored in only one trial,
which found that SDD substantially decreased coloniza-
tion with resistant organisms [1,25]. Recently, the largest
study up to now, a multi-center open-label, clustered
group-randomized, crossover study, analyzing data from
5,463 patients, who were in the ICU for more than
three days, found a decrease in acquired bacteremia and
respiratory tract colonization with highly resistant
microorganisms during SDD [26]. Although the use of
SDD can select resistant strains not susceptible to poly-
myxin or tobramycin [27], there are no indications that
SDD promotes tobramycin resistance.
Strength and limitations
The present study presents the largest cohort of criti-
cally ill patients up to now with serial serum tobramycin
measurements during SDD over a longer time frame,
and also the largest study that relates tobramycin leak-
age to markers of organ failure and clinical outcome. It
is the first study presenting urinary concentrations and
showing that these concentrations are substantial.
Furthermore, we used the most sensitive method to
detect serum tobramycin. Its limitation is that the analy-
sis of clinical variables associated with tobramycin leak-
age is difficult, because follow-up time varied between
patients due to differences in ICU stay. We, therefore,
choose two single markers of tobramycin leakage per
patient, a quantitative marker for correlation (the high-
est tobramycin concentration for each patient), and a
qualitative marker for comparing groups with and with-
out tobramycin leakage (at least once a positive serum
sample). We did not take into account the area under
the curve, because of a different follow-up between
patients. An additional difficulty in the interpretation of
associations between tobramycin leakage to clinical vari-
ables is the lag time between renal dysfunction and the
rise of tobramycin. This may explain why correlations at
the same day were less strong than those on the day of
ICU admission. Patients are generally the sickest at ICU
admission, while it takes some days before tobramycin
levels increase due to AKI. However, the results are bio-
logically plausible. Unfortunately, ototoxicity cannot be
monitored in critically ill patients, while renal toxicity
can only be assessed in a large prospective controlled
design if baseline renal function is documented. Poten-
tial toxicity can, however, not erase the positive effect of
SDD on infection prevention and patient outcome as
shown in previous studies [1,2].
Conclusions
The present observational cohort study in acutely
admitted critically ill patients receiving SDD shows that
trace amounts of the enterally administered tobramycin
were detectable in the serum of the majority of the
patients during the first week of ICU admission. Tobra-
mycin leakage was associated with the severity of shock
and inflammation at ICU admission and subsequent
AKI, suggesting gut barrier failure and subsequent
decreased removal. Unexpectedly, urinary tobramycin
concentrations were above the therapeutic trough level
in half of the patients. The presence of tobramycin in
urine in critically ill patients with gut barrier failure
likely contributes to the prevention of urinary tract
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Page 8 of 10colonization with tobramycin sensitive strains. The pre-
s e n tf i n d i n g sd on o ti n d i c a t et h a tw es h o u l ds t o pt r e a t -
ing our patients with SDD. However, they underscore
the potential of tobramycin leakage to the systemic cir-
culation and its possible systemic side effects. SDD
remains an important infection prevention strategy. To
prevent possible toxicity during prolonged use of SDD,
we should consider monitoring serum tobramycin con-
centrations in patients at risk and reducing the enteral
dose when serum concentrations remain > 1 mg/L.
Key messages
￿ During the use of selective decontamination of the
digestive tract (SDD), trace amounts of the enterally
administered tobramycin are present in the blood of
the majority of critically ill patients acutely admitted
to the ICU.
￿ Tobramycin leakage is associated with the severity
of shock and inflammation at ICU admission and
subsequent AKI; however, nephrotoxicity could not
be shown.
￿ Tobramycin leakage reflects loss of the gut barrier
and subsequent decreased removal.
￿ To prevent possible toxicity during prolonged use
of SDD, monitoring of serum tobramycin concentra-
tions in patients at risk should be considered, and
the enteral tobramycin dose reduced when serum
concentrations remain > 1 mg/L.
￿ Urinary tobramycin concentrations were above the
therapeutic trough concentration in half of the
patients during the first week of ICU admission and
may, therefore, contribute to the prevention of urin-
ary tract colonization with tobramycin sensitive
strains.
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